Donato Agnusdei, born in 1949, studied medicine at the University of Siena, Italy, and graduated in 1974. Currently, he works as a Senior Director of Global Medical External Relation Bone Muscle, Joint, and Autoimmune Diseases Platform Team, Eli Lilly and Company. he undertook a postdoctoral training in internal medicine and cardiology, and endocrinology. His academic research interests were devoted to the pathogenesis and treatment of postmenopausal osteoporosis. He serves as an Investigator and Study Coordinator in several international clinical trials on primary and secondary osteoporosis. In 1996, he Joined Eli Lilly and Company as a European Medical Coordinator. In 2000, he was appointed as a European Product Team Physician for Raloxifene and Teriparatide, and in 2001, he took the role of an Osteoporosis Consultant for Europe and Latin America. Since 2004, he has been a Medical Fellow for osteoporosis, Member of the Musculoskeletal Platform Team, and responsible for global projects. He holds the board memberships of IOF Committee Scientific Advisors, ISMNI, and ESCEO. he holds societies memberships of Endocrine Society, ASBMR, ECTS, IBMS, SIE, and SIOMMMS.
Biography Updated on 18 January 2011